Source: FirstWord Pharma

LUCA Science: LUCA Science and Kyowa Kirin Announce Joint Research Agreement on Mitochondrial Disease Treatment With Novel Mitochondria Modality

TOKYO--(BUSINESS WIRE)-- LUCA Science Inc. (LUCA Science, Tokyo, Japan) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, Tokyo, Japan, TSE:4151) are pleased to announce they have entered into a research collab...

Read full article »

LUCA Science's Competitors | LUCA Science's News | LUCA Science's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

President & CEO

Rick C. Tsai

CEO Approval Rating

90/100

Luca Science is a Japan-based biopharmaceutical company that develops and commercializes mitochondrial therapy for the treatment of damaged tissues and organs.